July 2020
Volume 6, Issue 8
This issue discusses palliative care and hematopoietic cell transplant, examines anticoagulation in patients with obesity, and more.
Table of Contents
July 2020 Issue
Editor’s Corner: Caring For Ourselves and Each Other in an Unprecedented Time
During the COVID-19 quarantine, my grandfather, the well-loved patriarch of our large family, passed away. It is difficult to process loss and grief over...
Shaping Public Health Policy During the Coronavirus Pandemic
Last year, the American Society of Hematology (ASH) selected Zachary Kiser, PhD, as its 2019-2020 ASH Congressional Fellow. The Congressional Fellow program aims to...
Reader Responses: Should this patient with DLBCL receive rituximab maintenance after R-CHOP?
Here’s how readers responded to a You Make the Call question about rituximab maintenance after R-CHOP for a patient with stage 4B diffuse large...
July 2020 Issue
Oral Apixaban Noninferior to Subcutaneous Dalteparin for Preventing Recurrent Cancer-Associated VTE
In patients with cancer-associated venous thromboembolism (VTE), treatment with oral apixaban was noninferior to subcutaneous dalteparin for the prevention of recurrent VTE, according to...
Daratumumab and Hyaluronidase-fihj Approved For Patients With Myeloma
The FDA has approved a new subcutaneous formulation of daratumumab and hyaluronidase-fihj for adult patients with newly-diagnosed or relapsed/refractory multiple myeloma (MM). Daratumumab was...
FDA Grants Orphan Drug Designation to MT-401 for AML
The FDA has granted orphan drug designation to MT-401, an allogeneic T-cell therapy for the treatment of acute myeloid leukemia (AML).
MT-401, from Marker Therapeutics,...
ASH Selects Next Congressional Fellow, and more
ASH Selects Next Congressional Fellow
Jerome Seid, MD, has been selected by the American Society of Hematology (ASH) to be the next ASH Congressional Fellow....
FDA Announces Plan to Relaunch Onsite Facility Inspections
The FDA has announced a partnership with the Centers for Disease Control and Prevention (CDC) to develop a plan for relaunching surveillance inspections. The...
Lenzilumab Demonstrates Clinical Benefit in Patients With Chronic Myelomonocytic Leukemia
A phase I study found that lenzilumab, an engineered human IgG1K monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), was associated with a clinical...
Radiation Alone Improves Outcomes in Early-Stage NLPHL Without High-Risk Features
Radiotherapy alone was associated with excellent progression-free survival (PFS) and low rates of late toxicity in patients with stages IA to IIA nodular lymphocyte-predominant...
Prophylaxis Does Not Fully Prevent VTE Risk in Patients With ALL Treated With Asparaginase
Antithrombin (AT) replacement and heparin prophylaxis was not entirely effective for the prevention of venous thromboembolism (VTE) in adult patients with acute lymphocytic leukemia...
CMS Leans Toward Permanent Expansion of Telemedicine Access
Massive expansion to telemedicine access by the Centers for Medicare and Medicaid Services (CMS) in the weeks since the coronavirus pandemic began has already...
Remembering Earl Davie, Clive Kearon, and more
Remembering Earl Davie, PhD (1927 – 2020)
Biochemist Earl Warren Davie, PhD, died on June 6, 2020, at the age of 92.Dr. Davie was Professor...
Methylprednisolone Augments IV Immune Globulin Response in Children With ITP
Intravenous immune globulin (IVIG) plus intravenous methylprednisolone (IVMP) confers a more rapid increase in platelet counts in children with immune thrombocytopenia (ITP), compared with...
International Prognostic Score Predicts Time to First Treatment in Patients With Early-Stage CLL
An international prognostic score (IPS-E) consisting of a sum score for three markers for consistently predicted time to first treatment (TTFT) in patients with...
Comparing Anticoagulant Effect of Edoxaban in Patients With Cirrhosis Against Healthy Controls
Edoxaban, an anti-factor Xa targeting direct oral anticoagulant (DOAC), is a less effective inhibitor of coagulation in patients with cirrhosis than in healthy individuals,...
Subcutaneous Daratumumab is Noninferior to IV Administration in Relapsed/Refractory Myeloma
Subcutaneous daratumumab was found to be noninferior to intravenous (IV) daratumumab in patients with relapsed or refractory multiple myeloma (MM), according to results from...
IWG-PM Publishes Proposed Diagnostic Criteria for SF3B1-Mutant MDS
The International Working Group for the Prognosis of MDS (IWG-PM) has published a proposal for new diagnostic criteria for SF3B1-mutant myelodysplastic syndromes (MDS) as...
July 2020 Issue
Pulling Back the Curtain: Cindy Dunbar, MD
In this edition, Cindy Dunbar, MD, discusses the personal experience that led her to hematology and her lifelong love of music.
What was your childhood like?
I...
Palliative Care and Transplant
Early palliative care integration has increased in oncologic settings but remains less common − and often misunderstood − in hematologic malignancies, especially for patients...
July 2020 Issue
How I Treat in Brief: Anticoagulation in Patients With Obesity
This month, Tzu-Fei Wang, MD, and Marc Carrier, MD, MSc, reviewed anticoagulation strategies for patients who are obese and therefore at risk of venous thromboembolism, atrial...
You Make the Call: Should this patient with DLBCL receive rituximab maintenance after R-CHOP?
This month Ann S. LaCasce, MD, MMSc, discusses whether a patient with high-risk DLBCL should receive rituximab maintenance after R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride,...
